Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PRCP | P42785 | 1/20 | 0.30 |
| ▸ | FDPS | P14324 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20833228 | 1.00 | KDM4E (0.41) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL7498448 | 0.94 | FDPS (0.36) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL22461930 | 0.94 | FDPS (0.36) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL5447760 | 0.81 | KDM4E (0.42) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL14622051 | 0.81 | KDM4E (0.42) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL20833286 | 0.80 | KDM4E (0.36) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL19387319 | 0.78 | KDM4E (0.35) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL13930842 | 0.78 | KDM4E (0.35) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL1266740 | 0.78 | — | — | |
| SCHEMBL2644164 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020191252-A1 | TECHNOLOGIES USEFUL FOR OLIGONUCLEOTIDE PREPARATION | WAVE LIFE SCIENCES LTD. (SG) | 2020-09-24 | — | — | WO | disclosed |
| US-20200231620-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | WAVE LIFE SCIENCES LTD. (SG) | 2020-07-23 | — | — | US | disclosed |
| WO-2019055951-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | WAVE LIFE SCIENCES LTD. (SG) | 2019-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200231620-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | POLRMT, DCLRE1B, RNGTT | KDM4E 3297/4885NPC1 1889/4885CYP1A2 4658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.